Pacific Biosciences Of California (PACB) Operating Leases (2019 - 2026)

Pacific Biosciences Of California's Operating Leases history runs 8 years deep, the most recent figure standing at $59.0 million for Q1 2026.

• In Q1 2026, Operating Leases rose 11.55% year-over-year to $59.0 million; the TTM figure through Mar 2026 stood at $59.0 million (up 11.55% YoY), while the FY2025 annual figure was $56.6 million, up 279.46% from the prior year.
• Operating Leases was $59.0 million for Q1 2026 at Pacific Biosciences Of California, up from $56.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $59.0 million in Q1 2026 to a low of $14.9 million in Q4 2024.
• Historically, Operating Leases has averaged $38.9 million across 5 years, with a median of $40.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Operating Leases plunged 52.81% in 2024, then soared 279.46% in 2025.
• A 5-year view of Operating Leases shows it stood at $41.1 million in 2022, then declined by 23.04% to $31.6 million in 2023, then slumped by 52.81% to $14.9 million in 2024, then jumped by 279.46% to $56.6 million in 2025, then gained by 4.26% to $59.0 million in 2026.
• The last three Operating Leases figures came in at $59.0 million (Q1 2026), $56.6 million (Q4 2025), and $54.3 million (Q3 2025), per Business Quant data.